Navigating the Rapidly Evolving Classification and Treatment Landscape of Secondary AML Subtypes: Modeling Best Practices for Early Identification and Individualized Care
| Overview / Abstract: |
Are you optimally treating secondary AML subtypes per latest evidence on selection of therapies? To optimize treatment, clinicians must not only have current knowledge of the up-to-date classification and risk stratification strategies, but the operational frameworks to effectively translate this latest evidence into treatment selection practices. Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create your own action plan to ensure your patients are benefitting from the latest advancements in care. |
|
Expiration |
Jun 14, 2025 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Online, Webinar / Webcast / Video |
|
Credits / Hours |
1.0 hours |
|
Accreditation |
ACCME, ANCC, MIPS QPP |
|
Presenters / Authors / Faculty |
Courtney DiNardo, MD, MSCE Jeffrey Lancet, MD |
|
Sponsors / Supporters / Grant Providers |
Provided by The University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL). This program is supported by an independent medical education grant from Jazz Pharmaceuticals. |
|
Keywords / Search Terms |
ACHL CME, CE, MD Anderson, Jazz, DiNardo, Lancet, acute myeloid leukemia, sAML, AML, t-AML, de novo AML, acute leukemia, subtype, classification, risk stratification, treatment landscape, clonal disorder, myelodysplasia, AML-MRC, cytotoxic chemotherapy, radiation therapy, hematologist, oncologist, pathologist Free CE CME |
|